Palantir’s chief executive, Louis Mosley, responds to criticism from a group of MPs that urges the UK government to cancel the company’s £330 million deal with the NHS. Mosley says calls to remove Palantir from the health service are “irresponsible” and could negatively affect patient care, arguing that the contract has delivered tangible outcomes. In support of this position, the reports cite Palantir’s claim that it has helped enable “110,000 extra operations.”
The MPs’ report, referenced in the coverage, questions whether the contract should continue, prompting public debate over the use of private technology in the NHS. While the outlets focus heavily on Mosley’s rebuttal, the central dispute remains over the value and impact of the government’s agreement with Palantir. Mosley’s comments frame the company as contributing to improved delivery within the NHS, whereas the MPs’ proposal would end or suspend the deal. The discussion centers on balancing promised operational benefits against concerns raised about the contract’s appropriateness and effectiveness.
